For cancer centers
Board-certified dermatologists. On site and by telehealth. 33 states. Backed by Oncology Ventures.
Four ways to start
01 · Any oncologist, nurse, or navigator
Your patients seen in days, not months.
A board-certified oncodermatologist for any skin, hair, or nail problem during treatment, by telehealth or on site, at no cost to your center. The note comes back to the treating oncologist.
Refer through TonoConnect →
02 · Treating teams
Patients who stay on therapy.
Rash, hand-foot syndrome, radiation dermatitis, and immunotherapy reactions graded and treated within days, so the drug is managed instead of held. A dermatologist your oncologists can call the same day.
Request a conversation →
03 · Infusion centers and survivorship
Infusion center support, and care after treatment.
Pre-emptive skin regimens for EGFR inhibitors and other high-toxicity agents, triage education for your nurses, and restorative oncodermatology for survivors: skin cancer surveillance, hair loss, scarring, and radiation skin change.
Set up support →
04 · Cancer center leadership
New patients, retained revenue, funded programs.
Our dermatologists find melanomas and high-risk skin cancers and send them to you. Infusions, visits, and follow-up stay in your center. And industry-funded supportive care pilots and toxicity research your oncologists co-author.
Talk to our leadership →
Board-certified. Trained at leading academic institutions. Every Tono dermatologist is selected and reviewed by our clinical leadership, and our supportive oncodermatology work is grounded in research collaboration with academic dermatology, including the Department of Dermatology at Mount Sinai.
Days to a dermatology appointment
Board-certified dermatologists and subspecialists
States in our clinical footprint
Patients cared for, with an 84 NPS among complex patients
The physicians
The dermatologists your oncologists will call.
A few of the dermatologists who lead our supportive oncodermatology work. Each was selected by our clinical leadership, and each is used to working inside an oncology team, on the toxicities of the drugs you prescribe.
Co-founder & Chief Medical Officer
Mondana Ghias, MD
Supportive oncodermatology, hidradenitis suppurativa, and complex medical dermatology. Einstein/Montefiore.
Supportive oncodermatology
Amy Thorne, DO
Supportive oncodermatology and inherited cancer syndromes. UT Health San Antonio; Department of Dermatology, MD Anderson Cancer Center.
Oncodermatology research
Brianna Olamiju, MD
Complex medical dermatology, oncodermatology, and skin of color. Over 25 peer-reviewed publications, including on dermatologic toxicities of chemotherapy.
Supportive oncodermatology
Nithin Reddy, MD
Supportive oncodermatology, autoimmune connective tissue disease, and dermatologic surgery. Tufts; Einstein, Academic Chief Resident.
Supportive oncodermatology
Yomna Amer, MD
Oncodermatology, hidradenitis suppurativa, and skin of color. Oregon Health & Science University.
Oncodermatology
Rachel Kang, MD
Complex medical dermatology and oncodermatology. Weill Cornell; NewYork-Presbyterian; Meyer Cancer Center research.
“Every dermatologist here was chosen because I would send my own family to them. For your patients that means one more thing: we know the drugs, and our first instinct is to treat the skin, not to stop the therapy.”
Mondana Ghias, MD
Co-founder and Chief Medical Officer, Tono Health
Meet the full physician group →
The evidence
Skin toxicity is common, visible, and one of the most preventable reasons a patient comes off therapy.
More than half of patients on EGFR inhibitors develop rash, and cutaneous reactions are among the most common and earliest immune-related adverse events of checkpoint inhibitors, where they are also associated with better survival. The right answer is to treat the skin, not stop the drug. After treatment the need continues: up to 59% of survivors report chronic skin problems, and 15 to 25% of women on aromatase inhibitors develop persistent hair loss, with almost no structured dermatology follow-up available.
Moderate and severe EGFR-inhibitor rash, reactive versus pre-emptive skin care (STEPP trial)
Continued anticancer therapy without interruption after rapid-access oncodermatology (2025 series, n=142)
Cutaneous adverse events resolved within three months of dermatology care, with only 9% needing systemic steroids
Survivors reporting chronic skin problems after treatment, most with no dermatology follow-up
What your center gains
Supportive oncodermatology during treatment. Restorative oncodermatology after.
One dermatology partner for the whole arc of cancer care: keeping patients on therapy while they are treated, and caring for what treatment leaves behind. Tono supplies the dermatologists, the toxicity expertise, and the coordination. Your center keeps the patient, the treatment plan, and the revenue.
Patients stay on therapy
Rash, pruritus, hand-foot reactions, nail and hair toxicity, immune-related skin events, and the skin complications of CAR T-cell and bispecific therapy, managed within days so dose holds and discontinuations become the exception.
Your oncologists get their time back
A dermatologist to call on the patient in the chair, grading and triage support for your nurses, and less reliance on systemic steroids.
Infusions, visits, and revenue stay with you
Continuity of therapy is continuity of infusion revenue. On-site clinic days can run under a professional services agreement at your center, and every note returns to the treating oncologist.
Restorative oncodermatology after treatment
Skin cancer surveillance, persistent hair loss, scarring, pigment change, and radiation skin damage, cared for by a board-certified dermatologist as part of survivorship, plus industry-sponsored research and pilots your center can join.
How it works
On site at your center. By telehealth in between. One team.
Most treatment-related skin toxicity is diagnosed by looking, grading, and knowing the drug, which is why supportive oncodermatology works so well by telehealth: a patient in the infusion chair or at home can be seen within days, often the same day, with photographs and video, and the plan returns to the oncologist. Our dermatologists also hold scheduled days inside partner centers for biopsies, procedures, and the patients who should be seen in person. Nothing to install, and no cost to get started.
A community oncology practice
Refer today and your patients are seen within days by telehealth, with the note back to you. As volume grows we add a physician-to-physician line, nurse triage support, and on-site days.
A multi-site oncology group
One dermatology partner across all of your sites, under a single agreement: telehealth everywhere, on-site clinic days at your largest centers, shared protocols, and one point of contact for your clinical leadership.
An academic or NCI-designated center
We extend the oncodermatology capacity you already have: overflow and survivorship visits by telehealth, coverage for your regional sites, and research collaboration on toxicity registries and supportive care studies.
Everything we can do together
No cost. No contract.
Getting started costs your center nothing. Refer a patient and we take it from there.
No IT project.
Nothing to install or integrate. We work through the referral and records you already use.
A dermatologist your oncologists can call.
Same day, on the patient in front of them, from a physician who knows the drugs and the toxicities.
Patients stay on therapy, and in your center.
Skin toxicity managed instead of the drug stopped. Infusions, visits, and follow-up stay with you.
01
Your patients seen in days, not months
A supportive oncodermatology visit within days, by telehealth or on site, at no cost to your center. Refer through TonoConnect, our physician portal, and follow the visit and the note from your desk.
Refer through TonoConnect →
02
A dermatologist on the phone today
Leave your number and a Tono dermatologist calls you back the same day, about a rash, a grade, or a hold decision, before you change the plan.
Request a call →
03
A conversation with our oncology leadership
A clinical conversation between your oncology leadership and ours about what a dermatology partnership would look like at your center.
Begin →
04
Survivorship skin care, after treatment
Send patients finishing treatment to a board-certified dermatologist for the follow-up survivorship guidelines call for: skin cancer surveillance, persistent hair loss, scarring, pigment change, and radiation skin damage.
Set up →
05
An oncodermatology clinic inside your center
Tono dermatologists on site at your center on scheduled days, with telehealth in between, so patients are seen where they are treated.
Set up →
06
Fewer holds: prevention protocols and team education
Pre-emptive skin regimens for EGFR inhibitors and other high-toxicity agents, and grading and triage education for your nurses and advanced practice clinicians.
Enquire →
07
Funded research and trials
Toxicity registries, supportive care studies, and industry-sponsored research with a national specialty group and academic dermatology collaborators.
Partner →
08
New patients, referred by Tono
Our dermatologists find melanomas, high-risk skin cancers, and patients who need oncology. Ask to be the center we send them to.
Join →
In practice
A leading community oncology group. The blueprint.
Tono is the supportive oncodermatology partner to a leading multi-site community oncology group in the Northeast, part of one of the largest independent oncology networks in the country. Tono dermatologists hold clinic days inside its cancer centers under a professional services agreement, with telehealth visits between them, so patients are seen where they are treated and within days of a referral. Oncologists, nurses, and navigators refer directly; every note returns to the treating oncologist; and the relationship has grown from patient care into shared research and industry-sponsored pilots. It is the model we bring to every cancer center we work with. Name and detail available on request. Tono is backed by Oncology Ventures.
Questions cancer centers ask
The details, before the first meeting.
What does Tono do for cancer centers?
Tono is a supportive oncodermatology partner for cancer centers and oncology groups. Board-certified dermatologists manage the skin, hair, and nail toxicities of cancer therapy so patients stay on treatment, by telehealth within days and on site at partner centers, and continue as the dermatology partner for survivorship care after treatment. Any oncologist can start by referring a single patient.
What is supportive oncodermatology?
The dermatologic care of patients during cancer treatment: preventing, grading, and treating the skin, hair, nail, and mucosal side effects of chemotherapy, targeted therapy, immunotherapy, and radiation, so the oncologist can keep the patient on the most effective regimen. Restorative oncodermatology continues that care after treatment, for persistent hair loss, scarring, pigment change, radiation skin damage, and skin cancer surveillance.
Which treatments cause skin toxicity?
EGFR inhibitors such as cetuximab, panitumumab, osimertinib, and amivantamab (acneiform rash, paronychia, fissures); immune checkpoint inhibitors such as pembrolizumab, nivolumab, and ipilimumab (rash, pruritus, vitiligo, lichenoid and bullous eruptions); CAR T-cell therapy and bispecific antibodies such as teclistamab (rash, cytokine-related eruptions, infections, nail changes); BRAF and MEK inhibitors; multikinase inhibitors and capecitabine (hand-foot syndrome); taxanes and anthracyclines (alopecia, nail changes); antibody-drug conjugates such as enfortumab vedotin; CDK4/6 inhibitors; aromatase inhibitors (persistent alopecia); radiation (dermatitis and fibrosis); and stem cell transplant (graft-versus-host disease of the skin).
Do you support patients on CAR T-cell therapy and bispecifics?
Yes. Cellular and T-cell-engaging therapies bring their own skin problems: rashes during and after cytokine release, drug eruptions, viral and fungal skin infections in immunosuppressed patients, nail and hair changes with bispecifics, and, later, an elevated risk of skin cancers that needs surveillance. Our dermatologists work alongside your cellular therapy team, by telehealth within days and on site where we hold clinic, so a skin finding is answered by a dermatologist rather than a hold.
Does telehealth work for treatment-related skin toxicity?
Yes. Most cutaneous toxicity is diagnosed visually and by history, which makes it well suited to a video visit with photographs. Patients are seen within days, often from the infusion chair, and the plan returns to the oncologist. When a biopsy, procedure, or hands-on exam is needed, our dermatologists see the patient in person on scheduled days at partner centers or arrange local care.
Who can refer, and how?
Oncologists, advanced practice clinicians, infusion nurses, and navigators. Refer through TonoConnect, our physician portal, where you can see the appointment, the note, and the plan, or send the referral the way you send any referral today. For a patient in the chair, request a same-day physician-to-physician call. A Tono care coordinator schedules the visit and closes the loop with your team.
Does it require an IT project or EHR integration?
No. Nothing to install and no integration to build. Referrals come in the way you send them today, and the note returns to the treating oncologist. Deeper connection is available for groups that want it later.
How quickly can a cancer center start, and what does it cost?
Referrals can begin this week, at no cost to your center. On-site clinic days, shared protocols, and research collaboration follow as the relationship grows, and can be structured under a professional services agreement.
Who is Tono right for?
Community oncology practices, multi-site oncology groups, and academic centers whose oncologists want a dermatologist they can call, and whose leadership wants patients to stay on therapy and in their center. Size and geography matter less than that.
Request a longer conversation
Referring a patient? Skip the form:
Refer Here→
